相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy
Edmund K. Bartlett et al.
CANCER (2020)
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors
Benoit Roch et al.
LUNG CANCER (2020)
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
Tatsuya Yoshida et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Kobe C. Yuen et al.
NATURE MEDICINE (2020)
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
Andressa S. Laino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer-associated cachexia
Vickie E. Baracos et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin
Gurpreet K. Arora et al.
JCI INSIGHT (2018)
Anamorelin (ONO-7643) for the Treatment of Patients With Non-Small Cell Lung Cancer and Cachexia: Results From a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Japanese Patients (ONO-7643-04)
Nobuyuki Katakami et al.
CANCER (2018)
Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer
Ugo Pastorino et al.
EUROPEAN JOURNAL OF CANCER (2017)
Connecting the Metabolic and Immune Responses to Cancer
Thomas R. Flint et al.
TRENDS IN MOLECULAR MEDICINE (2017)
Biomarkers of inflammation and breast cancer risk: a case-control study nested in the EPIC-Varese cohort
Claudia Agnoli et al.
SCIENTIFIC REPORTS (2017)
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Carlos Alfaro et al.
CANCER TREATMENT REVIEWS (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer
Charlotte Roach et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
C-Reactive Protein As a Marker of Melanoma Progression
Shenying Fang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
C-Reactive Protein Directly Suppresses Th1 Cell Differentiation and Alleviates Experimental Autoimmune Encephalomyelitis
Lin Zhang et al.
JOURNAL OF IMMUNOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer cachexia, mechanism and treatment
Tomoyoshi Aoyagi et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2015)
Cancer cachexia: understanding the molecular basis
Josep M. Argiles et al.
NATURE REVIEWS CANCER (2014)
Cancer cachexia-pathophysiology and management
Hajime Suzuki et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Kenneth C. H. Fearon et al.
CELL METABOLISM (2012)
An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
M. J. Proctor et al.
BRITISH JOURNAL OF CANCER (2011)
Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival
N. Fujitsuka et al.
TRANSLATIONAL PSYCHIATRY (2011)
Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis
Vickie E. Baracos et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2010)
Effects by Daily Long Term Provision of Ghrelin to Unselected Weight-Losing Cancer Patients A Randomized Double-Blind Study
Kent Lundholm et al.
CANCER (2010)
Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer
Giovanni Mantovani et al.
ONCOLOGIST (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Chemokine signaling via the CXCR2 receptor reinforces senescence
Juan C. Acosta et al.
CELL (2008)
Cancer cachexia:: Measured and predicted resting energy expenditures for nutritional needs evaluation
Gyasi Johnson et al.
NUTRITION (2008)
An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer
Donald C. McMillan
PROCEEDINGS OF THE NUTRITION SOCIETY (2008)
International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function
AP Davenport et al.
PHARMACOLOGICAL REVIEWS (2005)
The role of interleukin-8 in cancer cells and microenvironment interaction
A Yuan et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Ghrelin induces adiposity in rodents
M Tschöp et al.
NATURE (2000)
分享论文
